In the recent draft guidance on accelerated approval pathways, the FDA emphasizes heightened requirements for confirmatory trials and introduces a new process for expedited withdrawal of approval, establishing stricter requirements that biotechs must meet to maintain their accelerated approvals.
In this CMO Confidential video, Precision’s Chief Medical Officer and former FDA Oncology Division Director, Harpreet Singh, MD, highlights key takeaways and what this means for the biotech industry.
Watch now to learn more.
Offered Free by: Precision for Medicine
See All Resources from: Precision for Medicine
